Tasmina Ferdous Susmi1, Atikur Rahman1,2, Md Moshiur Rahman Khan1, Farzana Yasmin1, Md Shariful Islam3,4, Omaima Nasif5, Sulaiman Ali Alharbi6, Gaber El-Saber Batiha7, Mohammad Uzzal Hossain8. 1. Department of Genetic Engineering and Biotechnology, Faculty of Biological Science and Technology, Jashore University of Science and Technology, Jashore, 7408, Bangladesh. 2. Department of Fermentation Engineering, School of Biotechnology, Jiangnan University, Wuxi, China. 3. Department of Reproductive and Developmental Biology, Graduate School of Life Science, Hokkaido University, Sapporo, 5 Chome Kita 8 Jonishi, Kita Ward, Sapporo, Hokkaido, 060-0808, Japan. sharifbge@uky.edu. 4. Department of Biology, University of Kentucky, 101 T.H. Morgan Building, Lexington, KY, 40506-022, USA. sharifbge@uky.edu. 5. Department of Physiology, College of Medicine, King Saud University [Medical City], King Khalid University Hospital, PO Box 2925, Riyadh, 11461, Saudi Arabia. 6. Department of Botany & Microbiology, College of Science, King Saud University, P.O Box 2455, Riyadh, 11451, Saudi Arabia. 7. Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, AlBeheira, 22511, Egypt. 8. Bioinformatics Division, National Institute of Biotechnology, Ganakbari, Ashulia, Savar, Dhaka, 1349, Bangladesh.
Abstract
BACKGROUND: PDE9A (Phosphodiesterase 9A) plays an important role in proliferation of cells, their differentiation and apoptosis via intracellular cGMP (cyclic guanosine monophosphate) signaling. The expression pattern of PDE9A is associated with diverse tumors and carcinomas. Therefore, PDE9A could be a prospective candidate as a therapeutic target in different types of carcinoma. The study presented here was designed to carry out the prognostic value as a biomarker of PDE9A in Colorectal cancer (CRC). The present study integrated several cancer databases with in-silico techniques to evaluate the cancer prognosis of CRC. RESULTS: The analyses suggested that the expression of PDE9A was significantly down-regulated in CRC tissues than in normal tissues. Moreover, methylation in the DNA promoter region might also manipulate PDE9A gene expression. The Kaplan-Meier curves indicated that high level of expression of PDE9A gene was associated to higher survival in OS, RFS, and DSS in CRC patients. PDE9A demonstrated the highest positive correlation for rectal cancer recurrence with a marker gene CEACAM7. Furtheremore, PDE9A shared consolidated pathways with MAPK14 to induce survival autophagy in CRC cells and showed interaction with GUCY1A2 to drive CRPC. CONCLUSIONS: Overall, the prognostic value of PDE9A gene could be used as a potential tumor biomarker for CRC.
BACKGROUND:PDE9A (Phosphodiesterase 9A) plays an important role in proliferation of cells, their differentiation and apoptosis via intracellular cGMP (cyclic guanosine monophosphate) signaling. The expression pattern of PDE9A is associated with diverse tumors and carcinomas. Therefore, PDE9A could be a prospective candidate as a therapeutic target in different types of carcinoma. The study presented here was designed to carry out the prognostic value as a biomarker of PDE9A in Colorectal cancer (CRC). The present study integrated several cancer databases with in-silico techniques to evaluate the cancer prognosis of CRC. RESULTS: The analyses suggested that the expression of PDE9A was significantly down-regulated in CRC tissues than in normal tissues. Moreover, methylation in the DNA promoter region might also manipulate PDE9A gene expression. The Kaplan-Meier curves indicated that high level of expression of PDE9A gene was associated to higher survival in OS, RFS, and DSS in CRC patients. PDE9A demonstrated the highest positive correlation for rectal cancer recurrence with a marker gene CEACAM7. Furtheremore, PDE9A shared consolidated pathways with MAPK14 to induce survival autophagy in CRC cells and showed interaction with GUCY1A2 to drive CRPC. CONCLUSIONS: Overall, the prognostic value of PDE9A gene could be used as a potential tumor biomarker for CRC.
Authors: Sanzana Fareen Rivu; Mohd Nazmul Hasan Apu; Samia Shabnaz; Noor Ahmed Nahid; Md Reazul Islam; Mir Md Abdullah Al-Mamun; Zabun Nahar; Sikder Nahidul Islam Rabbi; Maizbha Uddin Ahmed; Mohammad Safiqul Islam; Abul Hasnat Journal: Cancer Epidemiol Date: 2017-05-26 Impact factor: 2.984
Authors: Daniele V F Tauriello; Sergio Palomo-Ponce; Diana Stork; Antonio Berenguer-Llergo; Jordi Badia-Ramentol; Mar Iglesias; Marta Sevillano; Sales Ibiza; Adrià Cañellas; Xavier Hernando-Momblona; Daniel Byrom; Joan A Matarin; Alexandre Calon; Elisa I Rivas; Angel R Nebreda; Antoni Riera; Camille Stephan-Otto Attolini; Eduard Batlle Journal: Nature Date: 2018-02-14 Impact factor: 49.962
Authors: Bernard Levin; David A Lieberman; Beth McFarland; Kimberly S Andrews; Durado Brooks; John Bond; Chiranjeev Dash; Francis M Giardiello; Seth Glick; David Johnson; C Daniel Johnson; Theodore R Levin; Perry J Pickhardt; Douglas K Rex; Robert A Smith; Alan Thorson; Sidney J Winawer Journal: Gastroenterology Date: 2008-02-08 Impact factor: 22.682
Authors: Chyke A Doubeni; Douglas A Corley; Virginia P Quinn; Christopher D Jensen; Ann G Zauber; Michael Goodman; Jill R Johnson; Shivan J Mehta; Tracy A Becerra; Wei K Zhao; Joanne Schottinger; V Paul Doria-Rose; Theodore R Levin; Noel S Weiss; Robert H Fletcher Journal: Gut Date: 2016-10-12 Impact factor: 23.059